2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

HDACs control the action of tumor-suppressor genes and oncogenes that ACY-1215 perform vital roles in tumorigenesis37 and as a result have been researched as thera read more...

2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

To validate the particular inhibitory ACY-1215 effect of ACY-1215 on HDAC6 action, we initial evaluated its impact on the acetylation of Î read more...

2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

Dexamethasone (Dex)–sensitive (MM.1S) and Dex-resistant (MM.1R) human MM cell lines ACY-1215 ended up provided by Dr Steven Rosen (Nor read more...

2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

It has been proven Preclinical activity, pharmacodynamic, and pharm read more...

2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

HDACs regulate the action of tumor-suppressor genes and oncogenes that ACY-1215 engage in crucial roles in tumorigenesis37 and therefore ha read more...

2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

To confirm the certain inhibitory ACY-1215 influence of ACY-1215 on HDAC6 exercise, we 1st evaluated its influence on the acetylation of α-tubulin. MM.1S cells read more...

2 years ago

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor

Dexamethasone (Dex)–sensitive (MM.1S) and Dex-resistant (MM.1R) human MM mobile lines ACY-1215 were provided by Dr Steven Rosen (Northwestern College, Chicago read more...